Takeda Pharmaceutical Company Limited

Nao Morishita

Koji Ono

Masahiro Ito

Toshio Tanaka

Hidekazu Tokuhara

Hiroshi Banno

Yasuyoshi Arikawa

Hironobu Maezaki

Takaharu Hirayama

Yasuhiro Imaeda

Yasuhiro Hirata

Nobuki Sakauchi

Yuta Tanaka

Nobuo Cho

Ryo Mizojiri

Moriteru Asano

Douglas Robert Cary

Akinori Toita

Hironori Kokubo

Jun Fujimoto

Takeshi Yamamoto

Minoru Nakamura

Masaki Seto

Kazuaki Takami

Masataka Murakami

Masaki Daini

Minoru Sasaki

Keiko Kakegawa

Satoshi Mikami

Zenichi Ikeda

Fumiaki Kikuchi

Tomohiro Ohashi

Takahito Kasahara

Florian Pünner

Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I):

Nitrogen containing heterocycles as CDK12 inhibitors

Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Heterocyclic compound

The present invention provides a compound having a glucosylceramide lowering action (e.g., promoting glucosylceramide metabolism, inhibition of glucosylceramide synthesis, promoting glucosylceramide catabolism, etc.), which is expected to be useful as an agent for the prophylaxis or treatment of lysosome diseases (e.g., Gaucher's disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

Growing community of inventors

Kanagawa, Japan

Nao Morishita